Streetbeat News

Products Services

CLDX

Celldex Therapeutics' Chief Medical Officer, Diane C. Young, highlights the potential of Barzolvolimab in addressing unmet medical needs. The drug shows profound and sustained results across all study endpoints, indicating its critical role for patients, families, and physicians.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 3:02 pm

CLDX

Celldex Therapeutics has reported safety concerns regarding its drug Barzolvolimab, noting side effects such as hair color changes, neutropenia, hypopigmentation, and nasopharyngitis. These side effects, although mild, could impact patient quality of life. The study shows benefits at 52 weeks but lacks long-term safety data.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 3:01 pm

MU

Micron Technology, Inc. (NASDAQ:MU) is set to release its Q4 earnings, with analysts expecting a significant improvement in earnings and revenue compared to the previous year. The company offers a modest dividend yield of 0.49%, and investors would need a substantial investment to earn $500 monthly from dividends. Micron recently expanded its product line with the Crucial P310 SSD, targeting PCs, laptops, and gaming consoles.

Portfolio Pulse from Avi Kapoor

September 25, 2024 | 2:59 pm

DFSV

PVH

China's Ministry of Commerce is investigating PVH Corp. over alleged discriminatory practices related to Xinjiang cotton, potentially impacting the company's market position. Despite this, PVH shares remain relatively flat, and the company has raised its earnings outlook.

Portfolio Pulse from Nabaparna Bhattacharya

September 25, 2024 | 2:57 pm

CLDX

Celldex Therapeutics presented positive 52-week results from its Phase 2 study of barzolvolimab for chronic spontaneous urticaria, showing 71% of patients achieved complete response. The treatment demonstrated rapid and durable improvement, was well tolerated, and is moving to Phase 3 trials.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 2:47 pm

TSLA

Large investors are showing interest in Tesla (NASDAQ:TSLA) with a mix of bullish and bearish options trades. Benzinga's options scanner detected 273 unusual trades, with a significant amount of money involved. The sentiment is split, with 47% bullish and 42% bearish. The trading activity suggests a focus on a price range between $10.0 and $400.0. Tesla's stock is currently trading at $254.82, up by 0.22%, but RSI indicates it may be overbought.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 2:46 pm

INTC

Recent options trading trends for Intel (NASDAQ:INTC) show a bullish sentiment among large investors, with 61% of trades being bullish. The trading activity suggests a price range of $13.0 to $36.0 for Intel in the coming months. Intel's stock price has increased by 4.53% to $23.84, with a high trading volume and potential overbought RSI indicators.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 2:46 pm

TSLA

Tesla is set to return to the Paris Motor Show in October after a six-year absence, showcasing its vehicles including the highly anticipated Cybertruck. The event adds to a busy month for Tesla, which includes its Robotaxi Day and third-quarter financial reports.

Portfolio Pulse from Chris Katje

September 25, 2024 | 2:44 pm

DRI

UBER

Darden Restaurants reported weaker than expected fiscal Q1 earnings due to a summer sales slump, with Olive Garden and fine dining experiencing declines. Despite this, Darden remains confident, reaffirming its fiscal 2025 guidance and announcing a partnership with Uber for delivery services.

Portfolio Pulse from Upwallstreet

September 25, 2024 | 2:37 pm

AMGN

Amgen's shares are declining due to atopic dermatitis data that failed to meet analysts' expectations, highlighting competitive pressures in the market.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 2:34 pm